Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Colorcon
Johnson and Johnson
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SEROSTIM LQ

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Serostim Lq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00071240 Growth Hormone to Increase Immune Function in People With HIV Completed EMD Serono Phase 2 2002-10-01 Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.
NCT00071240 Growth Hormone to Increase Immune Function in People With HIV Completed National Center for Research Resources (NCRR) Phase 2 2002-10-01 Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.
NCT00071240 Growth Hormone to Increase Immune Function in People With HIV Completed The J. David Gladstone Institutes Phase 2 2002-10-01 Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.
NCT00071240 Growth Hormone to Increase Immune Function in People With HIV Completed University of California, San Francisco Phase 2 2002-10-01 Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.
NCT00071240 Growth Hormone to Increase Immune Function in People With HIV Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2002-10-01 Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T cells. Since these cells are lost during the course of HIV infection, it is possible that growth hormone treatment could help restore the immune system. This study will determine whether the administration of growth hormone can increase the size and function of the thymus and cause an increase in the number of new T cells in the blood of people infected with HIV. Study hypothesis: Growth hormone treatment will enhance T cell production in HIV infected adults.
NCT00082628 Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients Completed EMD Serono Phase 3 2004-05-01 The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.
NCT00100698 Physiologic Growth Hormone Effects in HIV Lipodystrophy Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2004-01-01 This study will investigate long-term, low-dose growth hormone administration in HIV-infected patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We hypothesize that low-dose growth hormone will reduce visceral fat. Secondary endpoints will include measures of insulin-like growth factor-1 (IGF-1), glucose homeostasis, lipids, blood pressure,bone density, cardiovascular risk and safety parameters.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Serostim Lq

Condition Name

Condition Name for Serostim Lq
Intervention Trials
HIV Infections 5
Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) 2
Human Immunodeficiency Virus Infections 2
Body Weight Changes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Serostim Lq
Intervention Trials
HIV Infections 7
Lipodystrophy 3
Syndrome 3
Acquired Immunodeficiency Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Serostim Lq

Trials by Country

Trials by Country for Serostim Lq
Location Trials
United States 18
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Serostim Lq
Location Trials
New York 3
Massachusetts 2
California 2
Texas 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Serostim Lq

Clinical Trial Phase

Clinical Trial Phase for Serostim Lq
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 2
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Serostim Lq
Clinical Trial Phase Trials
Completed 7
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Serostim Lq

Sponsor Name

Sponsor Name for Serostim Lq
Sponsor Trials
EMD Serono 5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
The J. David Gladstone Institutes 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Serostim Lq
Sponsor Trials
Industry 5
Other 5
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.